Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.95-0.68 (-6.40%)
At close: 04:00PM EST
9.95 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300
https://www.bluebirdbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,201

Key Executives

NameTitlePayExercisedYear Born
Mr. Nick LeschlyPres & Director841.95kN/A1973
Mr. William D. Baird IIIPrincipal Financial & Accounting Officer718.61kN/A1972
Mr. Andrew ObenshainCEO & DirectorN/AN/A1974
Ms. Gina R. Consylman CPAChief Financial OfficerN/AN/A1973
Mr. Kasra KasraianSr. VP of Technical Devel. & OperationsN/AN/AN/A
Ms. Jessica WhittenChief Accounting Officer & Principal Accounting OfficerN/AN/A1976
Ms. Ingrid GoldbergVP of Investor RelationsN/AN/AN/A
Ms. Helen C. FuSr. VP, Gen. Counsel & Sec.N/AN/AN/A
Ms. Elizabeth PingpankDirector of Corp. CommunicationsN/AN/AN/A
Ms. Kathleen A. WilkinsonChief People OfficerN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

bluebird bio, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement